Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3887MR)

This product GTTS-WQ3887MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens; Chimeric
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ3887MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11027MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MCLA-128
GTTS-WQ11246MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI4736
GTTS-WQ33MR IVTScrip™ mRNA-Anti-S, 2130(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 2130
GTTS-WQ6247MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CR57
GTTS-WQ10559MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY­3074828
GTTS-WQ587MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ5849MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ2777MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-282
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW